Duality Biotherapeutics (FRA:4ZB) Revenue: € Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:4ZB Duality Biotherapeutics Inc FRA:4ZB
19 GF Score
Price €19.70
! 2 Warning Signs
View Full Analysis

What is Duality Biotherapeutics Revenue?

Duality Biotherapeutics FRA:4ZB +6.49% 19 Revenue is € Mil as of Jun. 2026. GuruFocus rates FRA:4ZB with a GF Score™ of 19/100. The stock has 2 warning signs investors should review.

Duality Biotherapeutics's revenue for the six months ended in Jun. 2026 was €27.4 Mil. Duality Biotherapeutics does not have enough years/quarters to calculate its revenue for the trailing twelve months (TTM) ended in Jun. 2026. Duality Biotherapeutics's Revenue per Share for the six months ended in Jun. 2026 was €0.30. Duality Biotherapeutics does not have enough years/quarters to calculate its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026.

During the past 12 months, the average Revenue per Share Growth Rate of Duality Biotherapeutics was -76.10% per year. During the past 3 years, the average Revenue per Share Growth Rate was 1043.50% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate using Revenue per Share data.

During the past 4 years, Duality Biotherapeutics's highest 3-Year average Revenue per Share Growth Rate was 1043.50% per year. The lowest was 1043.50% per year. And the median was 1043.50% per year.

Duality Biotherapeutics  (FRA:4ZB) Revenue Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:


Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.

Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.

Duality Biotherapeutics Revenue Related Terms

Duality Biotherapeutics Revenue Historical Data

* Premium members only.

The historical data trend for Duality Biotherapeutics's Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Duality Biotherapeutics Revenue Chart

Duality Biotherapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Revenue
0.23 233.24 249.37 228.25

Duality Biotherapeutics Semi-Annual Data
Jun25 Dec25 Jun26
Revenue 155.10 74.96 27.39

FRA:4ZB vs VRTX, REGN, MRNA: Revenue Comparison

For the Biotechnology subindustry, Duality Biotherapeutics's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Duality Biotherapeutics Revenue vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Duality Biotherapeutics's Revenue distribution charts can be found below:

* The bar in red indicates where Duality Biotherapeutics's Revenue falls into.


FRA:4ZB
19GF Score
Duality Biotherapeutics Inc FRA:4ZB
Revenue is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Duality Biotherapeutics Revenue Calculation

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Frequently Asked Questions Learn more about Revenue →
What does a Revenue of € Mil mean?
Duality Biotherapeutics (FRA:4ZB) has a Revenue of € Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on Duality Biotherapeutics and its competitors.
Is Duality Biotherapeutics' Revenue too high?
Duality Biotherapeutics' current Revenue is € Mil. Overall, Duality Biotherapeutics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Duality Biotherapeutics' Revenue compare to VRTX and REGN?
Duality Biotherapeutics' Revenue of € Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Biotechnology company?
A good Revenue depends on the Biotechnology industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on Duality Biotherapeutics and its competitors. Duality Biotherapeutics's current Revenue is € Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Duality Biotherapeutics stock overvalued right now?
Duality Biotherapeutics (FRA:4ZB) has a current Revenue of € Mil. The current Revenue is € Mil. Duality Biotherapeutics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For Duality Biotherapeutics (FRA:4ZB), the current Revenue is € Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Duality Biotherapeutics Business Description

Other Exchanges 09606:Hong Kong
Address No. 868 Yinghua Road, 11th Floor, Building A, Jian Gong Datang International Plaza, Pudong New Area, Shanghai, CHN
Duality Biotherapeutics Inc is engaged in the discovery and development of antibody-drug conjugate (ADC) therapeutics, focusing on treatments for cancer and other diseases. The company has a diversified pipeline of ADC candidates, including two core products: DB-1303/BNT323, a HER2-targeting ADC for cancers such as breast and endometrial cancer, and DB-1311/BNT324, a B7-H3-targeting ADC for multiple solid tumors. In addition, it has several other clinical-stage ADC candidates with therapeutic potential, as well as multiple preclinical ADCs, including candidates expected to enter clinical trials. Its key products, including DB-1303/BNT323, DB-1311/BNT324, and DB-1305/BNT325, have received Fast Track Designation, with DB-1303 being a late-stage candidate undergoing registrational studies.
19GF Score

Get the complete analysis for FRA:4ZB

Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€19.70
Price